Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 45, Issue 6, Pages 659-665Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0091270005276117
Keywords
ertapenem; pharmacokinetics; plasma; lung tissue; ELF; alveolar cells; CAP
Categories
Ask authors/readers for more resources
Ertapenem is approved for the treatment of community-acquired pneumonia ( CAP), but its in vivo penetration into lung tissue ( LT), epithelial lining fluid ( ELF), and alveolar cells ( AC) is unknown. Fifteen patients undergoing thoracotomy were treated with 1 g intravenously for perioperative prophylaxis. Bronchoalveolar lavage was performed 1, 3, and 5 hours after ertapenem infusion. Normal LT was sampled at the time of lung extraction. Blood was collected before and at different time points up to 24 hours after infusion. Mean concentrations of ertapenem in plasma, ELF, and AC were at 1.0 hour, 63.1, 4.06, 0.004 mg/L; at 3.0 hours, 39.7, 2.59, 0.003 mg/L; and at 5.0 hours, 27.2, 2.83, 0.007 mg/L. Mean ( range) concentration in LT was 7.60 ( 2.5 - 19.4) mg/kg tissue 1.5 to 4.5 hours after infusion. In plasma, ertapenem exhibited a C-max of 94.7 +/- 23.3 mg/L and an AUC(0-last) of 501.1 +/- 266.3 mg.h/ L. These results, combined with the reported ( MIC) 90 of most CAP bacteria, support the previously observed clinical efficacy of ertapenem in the treatment of CAP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available